Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programs

Sygnature Discovery is a world-leading integrated drug discovery contract research organization with sites in the UK and Canada and headquarters in Nottingham (UK), serving biotech and pharma customers across the United States, Canada, the United Kingdom and Europe. We undertake hit identification, hit-to-lead and lead optimization projects and complete drug discovery programs across a range of therapeutic areas. In support of this, we have expanded our assay capability to include the state-of-the-art ImageXpress(R) Micro COnfocal (IXM-C) high-content imaging platform to provide multi-dimensional, high-throughput screening solutions to facilitate in-house drug profiling, bioscience and DMPK in vitro activities. Here we demonstrate the application of our integrated imaging platforms including the IXM-C and associated MetXppress(R) Image acquisition and analysis software to multiple phases of the drug discovery process.